| NCT03409224 |
Differences in Immunologic Response to Cryoablation Versus Radiofrequency Ablation in the Treatment of Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03409224 |
Active, not recruiting |
University of California, Irvine |
2019-06-30 |
| NCT03395379 |
Air Dissection in Percutaneous Radiofrequency Ablation of T1a Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03395379 |
Completed |
Centre Hospitalier Universitaire de Nice |
2016-03-15 |
| NCT03293563 |
UroCCR Database: French Research Network for Kidney Cancer |
https://ClinicalTrials.gov/show/NCT03293563 |
Recruiting |
University Hospital, Bordeaux |
2021-12-31 |
| NCT03291028 |
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma |
https://ClinicalTrials.gov/show/NCT03291028 |
Recruiting |
Fox Chase Cancer Center |
2020-12-31 |
| NCT03226886 |
TRACERx Renal (TRAcking Renal Cell Carcinoma Evolution Through Therapy (Rx)) |
https://ClinicalTrials.gov/show/NCT03226886 |
Recruiting |
Royal Marsden NHS Foundation Trust |
2023-09-01 |
| NCT03161145 |
A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread |
https://ClinicalTrials.gov/show/NCT03161145 |
Completed |
Bristol-Myers Squibb |
2017-08-31 |
| NCT03140176 |
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy. |
https://ClinicalTrials.gov/show/NCT03140176 |
Recruiting |
Pfizer |
2020-12-30 |
| NCT03133286 |
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) |
https://ClinicalTrials.gov/show/NCT03133286 |
Recruiting |
DxTerity Diagnostics |
2019-09-06 |
| NCT03097601 |
ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib |
https://ClinicalTrials.gov/show/NCT03097601 |
Active, not recruiting |
Centre Antoine Lacassagne |
2019-12-30 |
| NCT03091465 |
Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib |
https://ClinicalTrials.gov/show/NCT03091465 |
Completed |
Spanish Oncology Genito-Urinary Group |
2017-04-17 |
| NCT03052504 |
Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy |
https://ClinicalTrials.gov/show/NCT03052504 |
Completed |
Aarhus University Hospital |
2018-02-28 |
| NCT02940639 |
Real-Life Efficacy and Safety of Nivolumab in Patients With Advanced/Metastatic Renal Cell Carcinoma After Prior Therapy |
https://ClinicalTrials.gov/show/NCT02940639 |
Recruiting |
Bristol-Myers Squibb |
2024-10-31 |
| NCT02923284 |
NANOTECH RCC Biomarkers |
https://ClinicalTrials.gov/show/NCT02923284 |
Completed |
Washington University School of Medicine |
2020-01-02 |
| NCT02848768 |
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02848768 |
Completed |
Rennes University Hospital |
2015-03-31 |
| NCT02809404 |
Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) |
https://ClinicalTrials.gov/show/NCT02809404 |
Completed |
Radboud University |
2016-01-31 |
| NCT02776644 |
Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan |
https://ClinicalTrials.gov/show/NCT02776644 |
Completed |
Pfizer |
2017-12-30 |
| NCT02732665 |
Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02732665 |
Recruiting |
Chalmers University of Technology |
2019-03-31 |
| NCT02732652 |
Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02732652 |
Recruiting |
Chalmers University of Technology |
2019-03-31 |
| NCT02664883 |
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer |
https://ClinicalTrials.gov/show/NCT02664883 |
Recruiting |
University of Southern California |
2020-09-08 |
| NCT02627144 |
Bevacizumab in Metastatic Renal Cancer |
https://ClinicalTrials.gov/show/NCT02627144 |
Completed |
Hoffmann-La Roche |
2014-09-30 |
| NCT00033137 |
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00033137 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT04353765 |
Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors |
https://ClinicalTrials.gov/show/NCT04353765 |
Recruiting |
Ipsen |
2020-12-30 |
| NCT00050752 |
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer |
https://ClinicalTrials.gov/show/NCT00050752 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT03628859 |
BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) |
https://ClinicalTrials.gov/show/NCT03628859 |
Recruiting |
Centre Leon Berard |
2023-06-30 |
| NCT00001238 |
Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders |
https://ClinicalTrials.gov/show/NCT00001238 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT02537743 |
Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02537743 |
Active, not recruiting |
iOMEDICO AG |
2020-12-31 |
| NCT02499458 |
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer |
https://ClinicalTrials.gov/show/NCT02499458 |
Completed |
Lawson Health Research Institute |
2018-12-31 |
| NCT02411968 |
Follow up After Cryoablation of Small Renal Masses. |
https://ClinicalTrials.gov/show/NCT02411968 |
Completed |
Radboud University |
2018-09-30 |
| NCT02370290 |
Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer |
https://ClinicalTrials.gov/show/NCT02370290 |
Completed |
University of Southern California |
2015-12-31 |
| NCT02315755 |
Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC |
https://ClinicalTrials.gov/show/NCT02315755 |
Completed |
Pfizer |
2017-11-20 |
| NCT02247583 |
Investigating Patient Satisfaction With Oral Anti-Cancer Treatment |
https://ClinicalTrials.gov/show/NCT02247583 |
Completed |
KU Leuven |
2013-07-31 |
| NCT02228954 |
IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC) |
https://ClinicalTrials.gov/show/NCT02228954 |
Active, not recruiting |
Radboud University |
2018-03-05 |
| NCT02187042 |
Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line |
https://ClinicalTrials.gov/show/NCT02187042 |
Completed |
Pfizer |
2018-07-25 |
| NCT02186925 |
A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney. |
https://ClinicalTrials.gov/show/NCT02186925 |
Recruiting |
Meir Medical Center |
2019-08-31 |
| NCT02184416 |
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting |
https://ClinicalTrials.gov/show/NCT02184416 |
Recruiting |
Pfizer |
2021-05-01 |
| NCT02156895 |
Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea |
https://ClinicalTrials.gov/show/NCT02156895 |
Recruiting |
Pfizer |
2021-08-21 |
| NCT02150369 |
Interleukin-2—Induced Cognitive/Affective/Sleep Symptoms |
https://ClinicalTrials.gov/show/NCT02150369 |
Completed |
Duke University |
2017-03-02 |
| NCT02143492 |
Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC |
https://ClinicalTrials.gov/show/NCT02143492 |
Completed |
Argos Therapeutics |
2015-07-31 |
| NCT02121730 |
Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions |
https://ClinicalTrials.gov/show/NCT02121730 |
Recruiting |
Centre Hospitalier Universitaire, Amiens |
2019-08-31 |
| NCT02086734 |
Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02086734 |
Completed |
Ludwig-Maximilians - University of Munich |
2018-07-31 |
| NCT02087852 |
Kidney Cancer DNA Registry |
https://ClinicalTrials.gov/show/NCT02087852 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-03-31 |
| NCT01773655 |
Clinical and Histopathologic Characteristics of BAP1 Mutations |
https://ClinicalTrials.gov/show/NCT01773655 |
Completed |
Memorial Sloan Kettering Cancer Center |
2020-06-30 |
| NCT01931644 |
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions |
https://ClinicalTrials.gov/show/NCT01931644 |
Recruiting |
Sanguine Biosciences |
2025-08-31 |
| NCT01917214 |
A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival |
https://ClinicalTrials.gov/show/NCT01917214 |
Completed |
Pfizer |
2014-03-31 |
| NCT01827254 |
Sutent Rechallenge In mRCC Patients |
https://ClinicalTrials.gov/show/NCT01827254 |
Completed |
Pfizer |
2014-04-30 |
| NCT01728948 |
Sorafenib in Elderly mRCC |
https://ClinicalTrials.gov/show/NCT01728948 |
Completed |
Bayer |
2016-01-04 |
| NCT01649778 |
Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01649778 |
Completed |
Novartis |
2017-07-03 |
| NCT01598597 |
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) |
https://ClinicalTrials.gov/show/NCT01598597 |
Completed |
Genentech, Inc. |
2014-11-30 |
| NCT01585974 |
Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01585974 |
Completed |
Bayer |
2015-06-30 |
| NCT01538823 |
Urine Proteome of Surgical Patients and Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01538823 |
Completed |
Washington University School of Medicine |
2016-07-31 |
| NCT01508364 |
Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01508364 |
Completed |
Bayer |
2013-12-31 |
| NCT01482520 |
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01482520 |
Completed |
Samsung Medical Center |
2013-09-30 |
| NCT01447199 |
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC) |
https://ClinicalTrials.gov/show/NCT01447199 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-09-30 |
| NCT01449825 |
Hepatic Monitoring for Pazopanib |
https://ClinicalTrials.gov/show/NCT01449825 |
Completed |
GlaxoSmithKline |
2013-12-31 |
| NCT01446224 |
Cardiovascular and Torsades de Pointes Monitoring for Pazopanib |
https://ClinicalTrials.gov/show/NCT01446224 |
Completed |
GlaxoSmithKline |
2013-12-31 |
| NCT01444456 |
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia |
https://ClinicalTrials.gov/show/NCT01444456 |
Completed |
Amgen |
2013-08-31 |
| NCT01415167 |
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy |
https://ClinicalTrials.gov/show/NCT01415167 |
Completed |
Prometheus Laboratories |
2018-04-30 |
| NCT01441661 |
Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01441661 |
Completed |
Cancer Foundation, China |
2012-06-30 |
| NCT01412671 |
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program |
https://ClinicalTrials.gov/show/NCT01412671 |
Completed |
Bayer |
2011-09-21 |
| NCT01405183 |
Association Between Hepatitis C Infection and Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01405183 |
Completed |
Henry Ford Health System |
2013-08-31 |
| NCT01398306 |
Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. |
https://ClinicalTrials.gov/show/NCT01398306 |
Completed |
University Medical Center Groningen |
2012-04-30 |
| NCT01392729 |
An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA) |
https://ClinicalTrials.gov/show/NCT01392729 |
Completed |
Hoffmann-La Roche |
2015-06-30 |
| NCT01390519 |
A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor |
https://ClinicalTrials.gov/show/NCT01390519 |
Completed |
Novartis |
2015-12-31 |
| NCT01381614 |
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS) |
https://ClinicalTrials.gov/show/NCT01381614 |
Completed |
GlaxoSmithKline |
2011-12-31 |
| NCT01381601 |
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics) |
https://ClinicalTrials.gov/show/NCT01381601 |
Completed |
GlaxoSmithKline |
2011-10-31 |
| NCT01367457 |
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus |
https://ClinicalTrials.gov/show/NCT01367457 |
Completed |
Pfizer |
2015-04-30 |
| NCT01370109 |
Cardiovascular Effects of Sunitinib Therapy (CREST) |
https://ClinicalTrials.gov/show/NCT01370109 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2017-12-31 |
| NCT01351571 |
An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01351571 |
Completed |
Hoffmann-La Roche |
2011-08-31 |
| NCT01339975 |
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01339975 |
Completed |
University Hospital, Bordeaux |
2014-05-31 |
| NCT01339962 |
Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. |
https://ClinicalTrials.gov/show/NCT01339962 |
Completed |
Pfizer |
2012-04-30 |
| NCT01328691 |
Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus |
https://ClinicalTrials.gov/show/NCT01328691 |
Completed |
Seoul National University Hospital |
2011-03-31 |
| NCT04416646 |
Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04416646 |
Recruiting |
Istituto Oncologico Veneto IRCCS |
2020-06-27 |
| NCT04415697 |
Identification of Predictive Gene Expression Profile of Sunitinib Response in Metastatic Clear Cell Renal Carcinomas |
https://ClinicalTrials.gov/show/NCT04415697 |
Completed |
Barretos Cancer Hospital |
2020-02-20 |
| NCT04392076 |
Image Guided RFA/MWA/CRYO of RCC Biomarker Profile Study |
https://ClinicalTrials.gov/show/NCT04392076 |
Recruiting |
University of Leeds |
2020-12-31 |
| NCT04377113 |
Cellular Immunity and Renal Cell Cancer |
https://ClinicalTrials.gov/show/NCT04377113 |
Recruiting |
Clinical Hospital Center Rijeka |
2020-12-31 |
| NCT04368546 |
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) |
https://ClinicalTrials.gov/show/NCT04368546 |
Active, not recruiting |
Charite University, Berlin, Germany |
2019-02-01 |
| NCT04375150 |
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC |
https://ClinicalTrials.gov/show/NCT04375150 |
Active, not recruiting |
Pfizer |
2021-03-02 |
| NCT04350047 |
Renal Cell Carcinoma and Stage IV Inferior Vena Cava Thrombus: Resection Without Thoracotomy |
https://ClinicalTrials.gov/show/NCT04350047 |
Completed |
Attikon Hospital |
2020-03-31 |
| NCT04309617 |
Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy |
https://ClinicalTrials.gov/show/NCT04309617 |
Recruiting |
Pfizer |
2020-04-15 |
| NCT04268368 |
Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors |
https://ClinicalTrials.gov/show/NCT04268368 |
Recruiting |
Università Politecnica delle Marche |
2021-01-01 |
| NCT04245410 |
Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04245410 |
Recruiting |
Universidad de Extremadura |
2020-03-01 |
| NCT04222374 |
Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC) |
https://ClinicalTrials.gov/show/NCT04222374 |
Recruiting |
University Hospital, Bordeaux |
2020-04-30 |
| NCT04213664 |
Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma. |
https://ClinicalTrials.gov/show/NCT04213664 |
Recruiting |
Corporacion Parc Tauli |
2020-01-02 |
| NCT04213157 |
Laparoscopic Partial Nephrectomy for cT1 Tumors |
https://ClinicalTrials.gov/show/NCT04213157 |
Completed |
Samsun Liv Hospital |
2019-08-30 |
| NCT04175262 |
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments |
https://ClinicalTrials.gov/show/NCT04175262 |
Completed |
Pfizer |
2020-03-09 |
| NCT04154163 |
Appropriate Dosing to Optimise Personalised Cancer Treatments |
https://ClinicalTrials.gov/show/NCT04154163 |
Recruiting |
University of Dundee |
2020-07-30 |
| NCT04147143 |
CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study |
https://ClinicalTrials.gov/show/NCT04147143 |
Recruiting |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2020-03-08 |
| NCT04113486 |
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations |
https://ClinicalTrials.gov/show/NCT04113486 |
Recruiting |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2021-09-30 |
| NCT04106349 |
Observational Real-life Study of Cabozantinib in Advanced Renal Cell Carcinoma (RCC) |
https://ClinicalTrials.gov/show/NCT04106349 |
Recruiting |
Ipsen |
2023-01-30 |
| NCT04115189 |
A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA) |
https://ClinicalTrials.gov/show/NCT04115189 |
Recruiting |
Pfizer |
2020-04-30 |
| NCT04076787 |
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib |
https://ClinicalTrials.gov/show/NCT04076787 |
Completed |
Pfizer |
2018-09-02 |
| NCT04053855 |
Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04053855 |
Recruiting |
Centre Hospitalier Universitaire de Saint Etienne |
2021-09-30 |
| NCT04043975 |
A Prospective Observational Study of Renal Cell Cancer Patients Treated With Nivolumab Plus Ipilimumab in the Real World Setting in Japan |
https://ClinicalTrials.gov/show/NCT04043975 |
Recruiting |
Bristol-Myers Squibb |
2022-08-01 |
| NCT04040530 |
Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours |
https://ClinicalTrials.gov/show/NCT04040530 |
Recruiting |
Region of Southern Denmark |
2021-09-01 |
| NCT04033991 |
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. |
https://ClinicalTrials.gov/show/NCT04033991 |
Active, not recruiting |
Pfizer |
2020-05-31 |
| NCT04006405 |
AURORAX-087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC |
https://ClinicalTrials.gov/show/NCT04006405 |
Recruiting |
Elypta |
2022-02-28 |
| NCT03981497 |
Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms |
https://ClinicalTrials.gov/show/NCT03981497 |
Recruiting |
IRCCS San Raffaele |
2024-02-28 |
| NCT03928964 |
MEtatastic Renal Carcinoma LINes |
https://ClinicalTrials.gov/show/NCT03928964 |
Active, not recruiting |
Centre Hospitalier Universitaire de Besancon |
2018-10-03 |
| NCT03916458 |
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA |
https://ClinicalTrials.gov/show/NCT03916458 |
Recruiting |
Pfizer |
2020-09-30 |
| NCT03891485 |
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy |
https://ClinicalTrials.gov/show/NCT03891485 |
Recruiting |
National Cancer Institute, Naples |
2020-12-31 |
| NCT03896958 |
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) |
https://ClinicalTrials.gov/show/NCT03896958 |
Recruiting |
SpeciCare |
2021-03-12 |
| NCT03776123 |
Post Marketing Surveillance to Observe Safety and Effectiveness of CABOMETYXâ„¢ in Korea. |
https://ClinicalTrials.gov/show/NCT03776123 |
Recruiting |
Ipsen |
2022-02-28 |
| NCT03748901 |
PD-L1 Expression in Japanese Renal Cell Carcinoma Patients |
https://ClinicalTrials.gov/show/NCT03748901 |
Active, not recruiting |
Chugai Pharmaceutical |
2019-12-31 |
| NCT03744585 |
Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts. |
https://ClinicalTrials.gov/show/NCT03744585 |
Completed |
Ipsen |
2019-06-07 |
| NCT03728842 |
Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03728842 |
Recruiting |
Indiana University |
2021-03-01 |
| NCT03734614 |
Preventive Effects of Aspirin as Adjuvant Therapy in Patients With Locally Advanced Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03734614 |
Recruiting |
RenJi Hospital |
2024-10-31 |
| NCT03696407 |
A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK |
https://ClinicalTrials.gov/show/NCT03696407 |
Completed |
Ipsen |
2019-08-01 |
| NCT03699579 |
Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC |
https://ClinicalTrials.gov/show/NCT03699579 |
Completed |
Ipsen |
2019-06-23 |
| NCT03694912 |
Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers |
https://ClinicalTrials.gov/show/NCT03694912 |
Recruiting |
Yonsei University |
2023-09-22 |
| NCT03670992 |
Surgical Treatment of Pancreatic RCC Metastases |
https://ClinicalTrials.gov/show/NCT03670992 |
Completed |
Azienda Policlinico Umberto I |
2017-01-10 |
| NCT03647878 |
Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. |
https://ClinicalTrials.gov/show/NCT03647878 |
Recruiting |
Ipsen |
2022-08-30 |
| NCT03663946 |
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread |
https://ClinicalTrials.gov/show/NCT03663946 |
Recruiting |
Bristol-Myers Squibb |
2021-12-31 |
| NCT02850809 |
Evaluation of the Efficacy of Radiofrequency in the Treatment of Renal Tumors |
https://ClinicalTrials.gov/show/NCT02850809 |
Completed |
University Hospital, Bordeaux |
2015-12-31 |
| NCT03630692 |
Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs |
https://ClinicalTrials.gov/show/NCT03630692 |
Recruiting |
Institut Cancerologie de l’Ouest |
2020-01-31 |
| NCT03568435 |
Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants |
https://ClinicalTrials.gov/show/NCT03568435 |
Active, not recruiting |
Bristol-Myers Squibb |
2020-12-31 |
| NCT03538717 |
“Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC” |
https://ClinicalTrials.gov/show/NCT03538717 |
Completed |
Pfizer |
2019-03-01 |
| NCT03519542 |
Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03519542 |
Completed |
Spanish Oncology Genito-Urinary Group |
2016-12-31 |
| NCT03471897 |
Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03471897 |
Completed |
Chalmers University of Technology |
2017-10-25 |
| NCT03455452 |
An Observational Study of Nivolumab in Participants With Advanced Kidney Cancer |
https://ClinicalTrials.gov/show/NCT03455452 |
Recruiting |
Bristol-Myers Squibb |
2022-01-18 |
| NCT03414827 |
Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03414827 |
Recruiting |
Zealand University Hospital |
2020-12-01 |
| NCT01246843 |
Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib |
https://ClinicalTrials.gov/show/NCT01246843 |
Completed |
Radboud University |
2011-04-30 |
| NCT01227213 |
The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01227213 |
Completed |
Radboud University |
2013-11-30 |
| NCT01236053 |
Cancer in Patients With Gabapentin (GPRD) |
https://ClinicalTrials.gov/show/NCT01236053 |
Completed |
GlaxoSmithKline |
2010-09-30 |
| NCT01210482 |
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) |
https://ClinicalTrials.gov/show/NCT01210482 |
Completed |
Pfizer |
2018-03-31 |
| NCT01173445 |
Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01173445 |
Completed |
University of Kansas Medical Center |
2011-05-31 |
| NCT01138124 |
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) |
https://ClinicalTrials.gov/show/NCT01138124 |
Completed |
GlaxoSmithKline |
2010-08-31 |
| NCT01135849 |
B-Receptor Signaling in Cardiomyopathy |
https://ClinicalTrials.gov/show/NCT01135849 |
Completed |
Stanford University |
2010-10-31 |
| NCT01087060 |
Detection of Renal Malignancy of Complicated Renal Cysts |
https://ClinicalTrials.gov/show/NCT01087060 |
Completed |
Seoul National University Hospital |
2008-03-31 |
| NCT01056263 |
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012 |
https://ClinicalTrials.gov/show/NCT01056263 |
Completed |
Pfizer |
2010-12-31 |
| NCT01026337 |
Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer |
https://ClinicalTrials.gov/show/NCT01026337 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2015-12-31 |
| NCT01028638 |
Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01028638 |
Completed |
University Medical Center Groningen |
2015-01-31 |
| NCT01014065 |
A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect) |
https://ClinicalTrials.gov/show/NCT01014065 |
Completed |
AHS Cancer Control Alberta |
2012-11-30 |
| NCT01012011 |
Regulatory Post Marketing Surveillance Study on Nexavar® |
https://ClinicalTrials.gov/show/NCT01012011 |
Completed |
Bayer |
2015-01-31 |
| NCT00980213 |
Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland |
https://ClinicalTrials.gov/show/NCT00980213 |
Completed |
Tampere University Hospital |
2013-11-30 |
| NCT00979381 |
Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor |
https://ClinicalTrials.gov/show/NCT00979381 |
Completed |
Radboud University |
2008-11-30 |
| NCT00979329 |
Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST |
https://ClinicalTrials.gov/show/NCT00979329 |
Completed |
Radboud University |
2011-12-31 |
| NCT00927043 |
Study Evaluating Renal Cell Carcinoma Risk Factors |
https://ClinicalTrials.gov/show/NCT00927043 |
Completed |
Pfizer |
2011-09-30 |
| NCT00918775 |
Follow-up After Metastasectomy in Patients With Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00918775 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-12-20 |
| NCT00900536 |
DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE |
https://ClinicalTrials.gov/show/NCT00900536 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00900276 |
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants |
https://ClinicalTrials.gov/show/NCT00900276 |
Completed |
Wake Forest University Health Sciences |
2011-04-30 |
| NCT00900042 |
SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00900042 |
Completed |
Southwest Oncology Group |
2002-12-31 |
| NCT00895674 |
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar |
https://ClinicalTrials.gov/show/NCT00895674 |
Completed |
Bayer |
2010-08-31 |
| NCT00876382 |
Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00876382 |
Completed |
SCRI Development Innovations, LLC |
2011-02-28 |
| NCT00873210 |
Study In Patients With Kidney Cancer Treated With Sutent |
https://ClinicalTrials.gov/show/NCT00873210 |
Completed |
Pfizer |
2011-11-30 |
| NCT00842790 |
Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging |
https://ClinicalTrials.gov/show/NCT00842790 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2014-07-31 |
| NCT03419572 |
Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03419572 |
Recruiting |
Ipsen |
2021-01-05 |
| NCT00836745 |
Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent |
https://ClinicalTrials.gov/show/NCT00836745 |
Completed |
Pfizer |
2012-07-31 |
| NCT00831857 |
VEGF Imaging in Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00831857 |
Completed |
University Medical Center Groningen |
2011-09-30 |
| NCT04295174 |
KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers |
https://ClinicalTrials.gov/show/NCT04295174 |
Completed |
Odense University Hospital |
2020-01-01 |
| NCT01982097 |
Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01982097 |
Completed |
Bayer |
2017-01-31 |
| NCT01557127 |
Nexavar Dosing in Renal Cancer Patients in “Real-life” Setting |
https://ClinicalTrials.gov/show/NCT01557127 |
Completed |
Bayer |
2014-05-16 |
| NCT00806650 |
Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00806650 |
Completed |
City of Hope Medical Center |
2017-11-15 |
| NCT01411423 |
Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan |
https://ClinicalTrials.gov/show/NCT01411423 |
Completed |
Bayer |
2012-03-16 |
| NCT02282579 |
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy |
https://ClinicalTrials.gov/show/NCT02282579 |
Completed |
Spanish Oncology Genito-Urinary Group |
2015-02-28 |
| NCT02533258 |
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice |
https://ClinicalTrials.gov/show/NCT02533258 |
Completed |
Pfizer |
2016-05-12 |
| NCT01934452 |
Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients |
https://ClinicalTrials.gov/show/NCT01934452 |
Recruiting |
Pfizer |
2021-12-01 |
| NCT04005183 |
Renal Cell Carcinoma Microenvironment Discovery Project |
https://ClinicalTrials.gov/show/NCT04005183 |
Recruiting |
University Health Network, Toronto |
2030-05-01 |
| NCT00771147 |
A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® |
https://ClinicalTrials.gov/show/NCT00771147 |
Completed |
Bayer |
NA |
| NCT00743054 |
microRNA Expression in Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00743054 |
Completed |
Sun Yat-sen University |
2009-08-31 |
| NCT00718367 |
Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens |
https://ClinicalTrials.gov/show/NCT00718367 |
Completed |
National University Hospital, Singapore |
NA |
| NCT00716625 |
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan) |
https://ClinicalTrials.gov/show/NCT00716625 |
Completed |
Pfizer |
2015-10-31 |
| NCT00700258 |
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] |
https://ClinicalTrials.gov/show/NCT00700258 |
Recruiting |
Pfizer |
2023-12-01 |
| NCT00684645 |
Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT® |
https://ClinicalTrials.gov/show/NCT00684645 |
Completed |
Pfizer |
2011-04-30 |
| NCT00656955 |
Follow-Up Study of Kidney Cancer Patients |
https://ClinicalTrials.gov/show/NCT00656955 |
Completed |
National Institutes of Health Clinical Center (CC) |
2013-05-31 |
| NCT00617799 |
Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma |
https://ClinicalTrials.gov/show/NCT00617799 |
Completed |
University of Nebraska |
2009-02-18 |
| NCT00513175 |
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia |
https://ClinicalTrials.gov/show/NCT00513175 |
Completed |
University of California, San Francisco |
NA |
| NCT00509704 |
Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00509704 |
Completed |
Radboud University |
NA |
| NCT00460798 |
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00460798 |
Completed |
Pfizer |
2009-09-30 |
| NCT00340457 |
Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States |
https://ClinicalTrials.gov/show/NCT00340457 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00216801 |
Relationship of Ochratoxin A to Upper Urologic Cancers |
https://ClinicalTrials.gov/show/NCT00216801 |
Completed |
Lawson Health Research Institute |
2007-04-30 |
| NCT00026663 |
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance |
https://ClinicalTrials.gov/show/NCT00026663 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00717743 |
T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY) |
https://ClinicalTrials.gov/show/NCT00717743 |
Completed |
National University Hospital, Singapore |
NA |